Monte Rosa Therapeutics (GLUE) Free Cash Flow (2020 - 2026)

Monte Rosa Therapeutics' Free Cash Flow history runs 7 years deep, the most recent figure standing at -$40.1 million for Q1 2026.

• In Q1 2026, Free Cash Flow rose 12.43% year-over-year to -$40.1 million; the TTM figure through Mar 2026 stood at -$17.3 million (down 148.89% YoY), while the FY2025 annual figure was -$22.9 million, down 154.71% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$40.1 million, up from -$42.7 million in the prior quarter.
• The five-year high for Free Cash Flow was $132.7 million in Q4 2024, with the low at -$45.8 million in Q1 2025.
• The 5-year median for Free Cash Flow is -$30.2 million (2024), against an average of -$11.1 million.
• The sharpest annual moves came in 2022 and 2024: Free Cash Flow tumbled 148.64% in 2022, then soared 1018.41% in 2024.
• Monte Rosa Therapeutics' Free Cash Flow stood at -$32.1 million in 2022, then surged by 136.93% to $11.9 million in 2023, then jumped by 1018.41% to $132.7 million in 2024, then slumped by 132.2% to -$42.7 million in 2025, then climbed by 6.13% to -$40.1 million in 2026.
• Business Quant data shows GLUE's Free Cash Flow at -$40.1 million in Q1 2026, -$42.7 million in Q4 2025, and $103.3 million in Q3 2025.